CD274 and ovarian cancer: A study that reported treatment results using atezolizumab, an anti-PD-L1 agent, and bevacizumab, an anti-angiogenesis agent, in advanced cervical cancer patients showed an ORR of 0%, which is significantly lower than results reported after using ICI and anti-angiogenesis drugs in endometrial cancer or ovarian cancer [70].